Living Proof has another $30 million in venture cash to get commercialization work in gear, while bankrolling some fresh efforts on the scientific side of the hair care venture.
Just about every biotech investor out there has been looking for just the right recipe of money, time and multiples to justify the high risk involved in betting on drug development. The decade-long cycle in search of a 10x or better return is in distinct disfavor now, with investors looking for tighter timelines and better odds in exchange for smaller but more predictable payoffs.
Jam "biotech" and "techie" together, and you get a term that might be twice as tricky to understand as either of those two words alone. Read the profiles in our second annual "Top 10 Biotech Techies" report and you'll see what this term means to us--people who combine the best of high technology and biotechnology to solve major problems in healthcare. Read the report >>
Elcelyx Therapeutics has landed a new investor as the biotech startup advances two lead products toward two major markets--weight management and diabetes.
Third Rock Ventures is committing $47 million to launch a startup biotech focused on cancer immunotherapeutics, one of the hottest fields in drug R&D today.
Lux Capital has nailed down a new fund, its first since 2007, to back startups in healthcare as well as energy and tech. With $245 million in commitments, more than the $200 million it originally targeted, Lux is closing its largest fund to date and staying the course with investments in biopharma.
The U.K.'s e-Therapeutics has raised $64 million to fuel midstage clinical development of a new cancer drug, which the biotech hopes to partner on around 2017.
Over the past few days I've met with dozens of people in the U.K.'s biotech industry, getting a crash course on the state of affairs here while getting a chance to offer a few opinions of my own on global drug development trends at a One Nucleus gathering at Canada House. More >>
Catabasis Pharmaceuticals has gone back to the well to raise close to $9 million, according to documents filed with the Securities and Exchange Commission.
Following a well-defined trail of venture groups into late-stage investing, San Francisco-based Foresite Capital Management says it has wrapped a $100 million fund that will be heavily focused on the most disruptive and most promising late-stage technology it can find in biotech, genomics and diagnostics, among other healthcare fields.